Objective: To assess the evidence for the cost-effectiveness of health behaviour interventions that address the major behavioural risk factors for chronic disease, including smoking, physical inactivity, poor diet, and alcohol misuse. Methods: Medical and economic databases were searched for relevant economic evaluations. Studies were critically appraised using a published 35-point checklist, and the results are described using a narrative approach, noting methodological limitations. The review included 64 studies from 1995-2005, including 17 reports on multiple behaviour interventions. Results: There was considerable variation among the studies by target populations, intervention components, primary outcomes, and economic methods, but the reported incremental cost-effectiveness ratios were consistently low (e.g. 5E14,000 per quality-adjusted life-year gained for smoking-cessation programmes in 2006 Euros) as compared to certain preventive pharmaceutical and invasive interventions. Interventions targeting high-riskpopulation subgroups were relatively better value for money as compared to those targeting general populations. Discussion: In general, the results of this review demonstrate favourable cost-effectiveness for smoking interventions, physical activity interventions and multiple behaviour interventions in high-risk groups. Although alcohol and dietary interventions appeared to be economically favourable, it is difficult to draw conclusions because of the variety in study outcomes. However, methodological limitations weaken the generalizability of findings, and suggest that the results of any given study should be considered carefully when being used to inform resource allocation.
INTRODUCTION
In the Western world, the key behaviours contributing to the largest disease burden include: tobacco smoking, physical inactivity, poor diet, harmful alcohol intake, drug use, vaccination practices, and sexual behaviours. [1] [2] [3] [4] In the USA, for example, the primary causes of death in 2000 were tobacco smoking (18%), poor diet and physical inactivity (16%), and alcohol consumption (3.5%). 2 Unlike other factors that impact upon health outcomes, such as genetic predisposition, ageing or cultural background, these health behaviours are potentially avoidable and modifiable. Clearly, a more preventive approach to health is crucial if public health is to improve in any sizeable way. 2 Despite a substantial body of literature confirming the efficacy of health behaviour interventions in smoking, physical activity, dietary intake and alcohol consumption, [5] [6] [7] [8] [9] [10] translation of these interventions into public health practice has been limited. Health behaviour interventions are the best way to both prevent and manage chronic disease. The current emphasis in the health behaviour intervention field is on converting this evidence into practice. 11 A key issue in this regard is the need for data on the cost-effectiveness of interventions to allow healthcare policy-makers to make informed decisions about the value of such interventions.
Three reviews exist on the economic evaluation results of smoking-cessation strategies. [12] [13] [14] An early review by Warner 13 concluded that smoking-cessation interventions delivered by general practitioners were highly cost-effective and remained the 'gold standard' in cost-effective healthcare. Similar conclusions were reached by Woolacott et al. 14 when reviewing interventions with multiple strategies delivered by a range of health professionals, and targeting specific types of smokers with an emphasis on pharmacological approaches and routine clinical care settings. In an attempt to improve the generalizability of cost-effectiveness findings from smoking-cessation programmes, Ronckers et al. 12 re-analysed findings to generate standardized cost-effectiveness ratios across settings, to help eliminate variation in programme effects and costing methods. However, huge variation among cost-effective ratios remained [i.e. US$490 to US$15,280 life-years saved (LYS)]. 12 Compared to many pharmaceutical treatments, surgeries and hospital-based healthcare services, the general consensus is that smoking-cessation strategies represent an excellent healthcare investment. 12, 13, 14 Four other reviews on the cost-effectiveness of preventive interventions are aimed at specific diseases: diabetes, 15 coronary heart disease, 16, 17 and atherosclerosis. 18 Addressing behavioural modification interventions for diabetes, Vijgen et al. reviewed three older studies on diabetes management and concluded that more research was needed, although they noted that the findings supported their cost-effectiveness. 15 Similarly, Brown et al. 16, 19 reviewed seven pre-1995 studies on coronary heart disease prevention, focusing on primary prevention strategies for smoking cessation and physical activity, and confirmed that general practitioner (GP)-delivered smoking-cessation interventions were highly cost-effective, but that further evaluations were needed for physical activity interventions.
The aim of this paper is to assess the evidence from economic evaluations of face-to-face behaviour interventions for smoking, physical inactivity, poor diet and alcohol misuse from reports published during 1995-2005. This paper provides a unique addition to the literature by consolidating the economic evaluation literature for all four behaviours, something not done in any previous review. We have focused on interventions delivered through face-to-face methods because this provides a more homogeneous group of interventions for comparison purposes, and because this was the most common intervention method during the period covered by the review.
METHODS
Interventions were included if: (1) they were an economic evaluation of a health behaviour change intervention for tobacco smoking or diet or physical activity or alcohol misuse behaviours or any combination of these behaviours; (2) interventions were delivered face-to-face; (3) interventions were aimed at individual-level behaviour change (rather than system-level or environmental changes, e.g. mass media campaigns); and (4) studies were published in the English language from 1995 to 2005 inclusive. We have included studies involving behaviour change interventions if they were either the focus of the study or one of the comparator interventions, because face-to-face behavioural interventions are often used in conjunction with other technologies (i.e. pharmacotherapies, surgery). This time frame was chosen because standardized methods for the conduct and reporting of economic evaluations in healthcare were not available until 1987 and were not widely adopted until several years later. 20 We excluded non-English-language studies because we did not have the resources to translate these reports. Studies of both healthy populations (i.e. primary prevention) and those with or at risk of a disease (i.e. secondary prevention) were included. Furthermore, where studies involve persons with or at risk of disease, we have focused on cardiovascular diseases, obesity, diabetes and cancer, because they incur the most costly health burdens in developed nations. For reports of interventions where two papers were published on the same study but report on different effectiveness measures, we have included only one report, and favoured outcomes in the generic outcome measure 'quality-adjusted life-years gained' (QALYs). Studies were excluded if the report had insufficient data for assessment of the economic evaluation, i.e. one or two brief paragraphs on the economic methods and outcomes. Partial economic evaluations do not provide efficiency information for resource allocation decisions, so these studies were excluded. Specifically, this meant that studies describing only the costs of the intervention without health outcomes or studies that evaluated the costs and health benefits of one intervention with no mention of a comparator(s) were excluded. In addition, to preserve the quality of the studies chosen for the review, we also excluded studies that did not synthesize cost and health outcomes data into a summary measure for the economic evaluation; that is, no cost-effectiveness ratios were produced.
In the first instance, the National Health Service-Economic Evaluation Database (NHS-EED) (http://www.york.ac.uk/inst/ crd/crddatabases.htm#NHSEED) was used to identify relevant manuscripts. This has an international focus, and includes studies of economic evaluations selected from a range of electronic databases (such as MEDLINE and EMBASE, Cochrane Library, PsychLit, Biomed Central), together with searching paper-based journals and other grey literature (e.g. working papers at centres of health economics research). The NHS-EED reviews provide a structured abstract that separately considers the quality of the evidence of clinical effectiveness in addition to the economic evidence while providing an independent critical assessment of the study's overall quality. Medical databases were also searched, due to the delay between the original research being published and the production of NHS-EED review abstracts. Reference lists of articles retrieved were hand-searched for additional relevant studies. Specific search terms, results and reasons for exclusions are listed in Appendix 1.
It is beyond the scope of this paper to discuss in detail the standard 'best-practice' methods for economic evaluations, and the reader is referred to other quality resources on this topic. 21, 22 Briefly, good-practice economic evaluations are transparent with respect to the policy question and perspective taken, adequate description of all comparators, detailed costing and health benefit methods, incremental cost-effectiveness ratios (ICERs) (see Appendix 2) and detailed sensitivity analyses. An ICER provides information on the efficiency of one option as compared to another by summarizing its relative value for money. An average cost-effectiveness ratio is the same as an ICER; however, it compares an intervention with baseline or zero ('do nothing') alternative. 23 Ratios of up to US$50,000 (E36,767) per QALY gained would generally be considered economically attractive, although this is a crude and arbitrary benchmark. 24 Sensitivity analyses test the stability of the ICERs by varying the point estimates used in the main analysis and are adequately justified (e.g. different effectiveness estimates from other epidemiological data, low and high confidence intervals, different possible costs or quantities of resources used). These analyses are performed to deal with the uncertainty within the data estimates and intervention protocols that commonly occur in economic evaluations. Relevant studies were critically appraised using the British Medical Journal's 35-point checklist for reporting economic evaluations (http://bmj.bmjjournals.com/ advice/checklists.shtml). 25 Studies were categorized by behaviour type, tabulated according to key features and outcomes and synthesized using a narrative approach. A narrative synthesis method was necessary because of the wide variability in economic study methods, outcomes and levels of quality, and because many economic evaluations include their own synthesis (meta-analyses) of epidemiological data for intervention efficacy and other data estimates. In addition to presenting the key findings in their original local currency and price year, ICERs were converted to 2006 Euros (using inflation deflators for individual countries and purchasing power parities), 26 where possible, to facilitate comparisons across studies. We also present the time horizon for the economic evaluation, any assumptions on intervention compliance or relapse behaviours, and any assumptions on long-term efficacy.
RESULTS
Of the 586 articles identified, most were excluded because they did not concern one of the four behaviours, were not economic evaluations, or were only partial economic evaluations (e.g. cost studies) (see Appendix 1) . Two studies were discarded because they had been amended and re-published when follow-up data became available, 27, 28 and an additional two because later reports published outcomes in terms of QALYs gained. 29, 30 This left a total of 64 articles in the review. For each behaviour type, the number of studies were as follows: smoking cessation, 15; physical activity, 13; alcohol, 12; and nutrition, 7. An additional 17 interventions simultaneously addressed more than one of these four behaviours and were categorized as 'multiple behaviour interventions' (Tables 1-5).
Smoking-cessation Interventions
Smoking-cessation strategies were composed of counselling by a range of health professionals, with or without nicotine replacement therapy (NRT) or bupropion, printed materials or telephone quit lines, and targeted certain types of smokers: highly addicted, new smokers, pregnant women, relapsers, and potential relapsers ( [32] [33] [34] [35] 37 and cost per quitter ranged up to E5398 33 (2006 Euros), with ranges depending on age and gender. Cost-effectiveness ratios were higher for interventions combining NRT with counselling as compared to counselling alone. Unfortunately, in eight studies there was limited information reported on the quality, detail, justification or synthesis of estimates for the effectiveness of the interventions. [31] [32] [33] 35, 36, [39] [40] [41] Costs were of limited scope for two studies, 32, 35 or costing methods were inadequately reported for two studies. 32, 40 Sensitivity analyses were incomplete in one study 42 and non-existent for two studies. 31, 32 In one study, 43 costs were not discounted because of the short time frame of the costing period (up to 1 year); however, effects were discounted, making the analysis inconsistent and against current recommendations. 22 Other limitations were a failure to state the economic perspective for three studies, 31, 43, 44 no price year provided for one study, 37 and inadequate descriptions of the interventions in one study. 31 
Alcohol Interventions
Alcohol interventions were composed of physician counselling techniques aimed at either hospital patients, families or adolescents ( 46 and UKATT 49 evaluating family physician counselling programmes were the diverse and large samples (n % 750), 4-year follow-up rates, randomized designs, and intention-to-treat procedures. Three studies reported average ratios, 45, 48, 53 two did not undertake sensitivity analyses, 48, 53 one inadequately addressed issues of nonrandomized samples or small samples, 48 and two others provided no price year, [54] [55] [56] making price conversions difficult.
Physical Activity Interventions
Interventions included a range of targets (e.g. from moderate intensity of physical activity to vigorous exercise) and delivery methods (e.g. health professional advice, group sessions and nurse-led home-based programmes), and were aimed at a wide variety of target populations, including those with or without chronic illnesses (Table 3) . Incremental costs per LYS were in the range E1845 to E47,515, [57] [58] [59] and cost per QALY gained was E2162 to E53,119 50,60-63 (2006 Euros). Cost savings per incremental unit of improved physical activity scores were found in one study 64 (2006 Euros) . Very small between-group differences, of questionable clinical importance, were found for one study assessing two rehabilitation programmes for breast cancer as compared to usual care. 62 de Vries et al. 61 found exercise training to be highly cost-effective when compared to two vascular operations for persons with coronary artery disease. From the employer's perspective, and using cost-benefit analysis where benefits were measured in cost savings from reductions in sick leave payments, physical activity counselling produced net savings of E305 per participant over 9 months. 65 The analytical perspective used (i.e. service provider, society or consumer, etc.) was unclear for three studies, 58, 66, 67 and often the quantity of resources used and costs were not reported separately. 58, 60, 62 Overall, sensitivity analyses were adequately reported, as were the methods for the estimation of costs and measures of effectiveness.
Diet Interventions
Counselling interventions with various health professionals were targeted at persons with diabetes or at high risk of developing diabetes, 68, 69 persons with heart disease/ obesity, 70 and overweight children 71 or adults 72 (Table 4 ). Average costs per mg/dl change in fasting glucose levels were E5.04
for the dietitian programme v. E6.64 for the basic care programme (2006 Euros). 68 In another evaluation, 71 average costs per '% decrease in energy from fat' over 12 months were E161 for a parent/child intervention versus E101 for counselling (2006 Euros). Tsai et al. found that a low-carbohydrate dietary intervention was dominant over a standard diet, but the differences in costs and in QALYs across the two options were not statistically significant. 73 For a dietitian counselling plus multidisciplinary care intervention, the incremental cost per patient achieving glycaemic control was E3705 (2006 Euros). 69 Counselling by a family practitioner was more cost-effective than counselling by a dietitian, with an incremental cost-effectiveness ratio of E1199 v. E8757 per LYS respectively, 70 and involved very small gains in terms of LYS (i.e. 14-22 days). Better health outcomes were found if a family physician was the sole provider 70 or aided a dietitian with nutrition counselling; however, costs were also higher. 70, 72 Sensitivity analyses were not undertaken or were weak, 68, 71, 72, 74 costs were inadequately reported, 69, 72 and, with one exception, 73 all studies had short time frames (1 or 2 years), with no attempt to estimate longer-term costs and outcomes.
Multiple Behaviour Interventions
Multiple behaviour or lifestyle interventions included different combinations of behaviour modification with or without health checks, pharmacotherapies, or surgery to improve health behaviours in general populations [75] [76] [77] [78] [79] or those with common chronic diseases ( Table 5 ). Most multiple behaviour studies employed risk factor modelling techniques to estimate survival outcomes, and many used Markov or simulation modelling [78] [79] [80] [81] [82] [83] to address the uncertainty of evaluation estimates ( 77 reported that if their GP-delivered lifestyle intervention was targeted at highrisk men, the incremental cost-effective ratios were E53,569 per LYS and E40,094 per QALY gained (2006 Euros) as compared to routine care. Four studies were found to have weak or no sensitivity analysis, 77, [86] [87] [88] and two studies lacked sufficient detail on costing methods. 77, 89 Generally, authors presented little or no information on the quality, structure or validity of the economic models used. Interventions aimed at men were more cost-effective than those for women in two studies. 75, 77 One study performed a cost-benefit analysis of a school-based obesity programme measuring benefits as reduced costs for medical and productivity costs avoided, and found, with 80% probability, net savings to society.
DISCUSSION
To our knowledge, this is the first review of the growing cost-effectiveness literature on face-to-face health behaviour interventions targeting smoking, physical inactivity, poor diet, and alcohol misuse. Consistent with previous reports, 12, 13, 14, 57 and subject to the limitations identified above, economic evaluations of smoking-cessation interventions showed them to be excellent and economically attractive public health investments (i.e. E14,000 per QALY gained, 2006 Euros). For the evaluations of alcohol interventions, net cost savings to society were found in four studies, favourable cost-effectiveness ratios (5E23,865 per QALY gained) in two others, and relatively high cost-effectiveness ratios (E72,473 per year of life in disability averted for optimal care v. no treatment) in one study. The findings for physical activity interventions generally indicated favourable cost-effectiveness (5E53,119 per QALY gained), and two studies showed net cost savings. For the dietary interventions, ICERs were not produced for three of the seven studies, and different outcome measures made it difficult to draw any conclusions. However, one study showed cost-effectiveness findings of E8757 per LYS.
Incremental cost per QALY ratios for multiple behaviour interventions targeting high-risk populations ranged from cost saving to E40,094 (2006 Euros). They were mostly cost-effective and higher than for smoking-cessation interventions alone.
No study explicitly addressed the possibility that multiple behaviour interventions may produce greater efficiencies as compared to single behaviour interventions. While many individuals engage in a range of risk factor behaviours, 90 multiple behavioural interventions or 'lifestyle' interventions may be the logical way forward, since they are risk factors for most chronic diseases. They also interact with each other throughout the lifecycle 91 and increase overall absolute risk for chronic diseases. Behaviour management play a crucial role in primary and secondary prevention of chronic disease. Other treatment strategies that aim to modify single risk factors are found to have incremental costeffectiveness ratios over E85,000 per LYS, including some hyperglycaemic drugs to lower blood glucose (pioglitazone and nateglinide), 15 anti-hypertensive drugs (calcium channel blockers, antiadrenergics), 16 and cholesterol-lowering drugs (colestipol, cholestyramine). 16 Overall, the behavioural interventions aimed at populations with high-risk factors for disease were more cost-effective than those aimed at healthy individuals, due to the larger health gains produced in these targeted cohorts. For example, middle-aged men often engage in multiple poor behaviours, 90 and therefore stand to gain more when they change to healthy lifestyles, which produces lower ICERs as compared to other cohorts. 92 Owing to the limited number of studies involving lower socio-economic subgroups, known to have poorer health behaviours, further work is needed to determine the economic findings attributable to disadvantaged populations and the related issue of equity in resource distribution. This issue is especially important when translating an intervention into a different setting.
Generally, the costs of the behavioural interventions reviewed were low relative to those for other healthcare interventions such as pharmaceutical management. Interventions were primarily of a counselling nature, low-technology, community-based and did not require extensive capital outlays. Despite this, many studies in this review also showed that behavioural interventions alone had lower effectiveness (for example, counselling alone for smoking cessation had lower effectiveness than when combined with NRT), and it is the overall cost-effectiveness ratios that are important rather than simply costs. With the exception of some interventions with longer follow-up contacts, the interventions were also short term and, unlike other health interventions (e.g. pharmaceuticals), where resources are required for the remainder of an individual's life, total lifetime expenditure was small. However, the costs of human resources for communitybased health providers should not be trivialized, as these organizations may find that operational costs (in terms of staff training, adequate salaries to promote staff retention, time and space to implement interventions, etc.) are relatively high. Few studies in the review included indirect costs such as potential cost-savings due to better health and lower use of health services or future healthcare costs associated with living longer.
An important part of cost-effectiveness analyses of behavioural interventions is establishing the link between behaviour change and long-term mortality and quality of life outcomes. The studies here have drawn on both trial evidence and epidemiological data to support these links; however, relatively weak evidence is available for the long-term health effects of physical activity, diet and drinking as compared to smoking cessation. 93 Economic outcomes here for alcohol, diet and physical activity interventions are generated over the short term, aligning with the intervention follow-up times, and do not attempt to predict longer-term effectiveness or maintenance of healthy behaviours. Despite the interventions being non-invasive and having minimal risk of adverse events, their effects are usually small across time and across treatment options (for example, a 5% smokingcessation rate at 12 months is considered to be clinically meaningful, although this small gain translates to relatively high numbers of LYS). This is a reflection of the difficulty in modifying health behaviours in populations, including persons with confirmed risk factors for chronic disease and also by the 'natural' health gains occurring in the comparison groups (e.g. unaided smoking quit rate, physical activity improvements in 'usual care' groups). New epidemiological data are constantly emerging to challenge cost-effectiveness outcomes, despite the conservative health effect estimates often used and the use of sensitivity analyses. For example, Yudkin et al. 9 reported a 7-year smoking relapse of 54%, and the studies in this review used estimates ranging from 0% to 40%; 29, 32, 37, 38, 40, 41, 95 because of this, underestimated cost-effectiveness ratios were produced.
When comparing these cost-effectiveness results across studies, particular care should be taken to acknowledge the different methods used, and the different cost types, outcomes and baselines. Hence, a simple comparison of ICERs should be avoided. Generalizing the results of many or any one study from this review will require economic re-analysis to reflect local conditions, particularly as the evidence base for the effectiveness of the interventions is constantly changing. Issues contributing to the generalizability and variation in cost-effectiveness ratios reported here include differences in: healthcare systems, incentives to healthcare professionals and institutions, clinical practice, population demographics, population values, target populations, risk factor profiles, disease prevalence, currency purchasing powers, and the availability of and access to new technologies 96 (see Cornuz et al. for a recent multinational comparison of pharmacotherapies for smoking cessation). 92 The decision to implement a programme will also involve ethical and political considerations, and issues such as equity, reach, needs, and priorities. These factors mean that the programme with the lower cost-effectiveness ratio may not always be the best one (see Bala and Zarkin 97 for a further discussion). The studies in this review typically omit cultural minorities and disadvantaged populations known to have increased levels of high-risk behaviours. 98 However, serving these disadvantaged populations may involve higher costs in reaching these subgroups and providing more intensive interventions to maintain behavioural change. 99 Finally, the mix of strategies to control for many chronic diseases in practice may be more complex than those described in the studies here. They may involve multiple methods (pharmacotherapy, behavioural therapy, and surgery), and additive effects and additional costs may therefore need to be considered.
Study Limitations and Strengths
Retrieval of all possible papers was limited to those referenced in medical databases and excluded those located in the grey literature (outside that performed by NHS-EED) and those produced in monographs and books. All papers published after 1995 in Englishlanguage journals were included. A quality grading system was not employed, because none are extensively used or widely validated, 100, 101 and there are limitations with using such a system, as important information may be missed in the reduction and categorization process. 101 However, a comprehensive checklist was used to establish the methodological quality and/or reporting of methods in an explicit and standardized way, and revealed a number of methodological limitations. The overall quality of the economic evaluations varied widely across and within each behaviour category. This review targets clinicians, behavioural scientists, and public health researchers. The information will be most useful for decision-makers wanting to know which interventions are the 'best buys' when making investments in preventive public health. A study of interest may be identified as appropriate for a particular setting and, following some re-analysis to reflect local conditions, the intervention may be considered by policy-makers for translation into practice. The review may also act as a reference guide for behavioural interventions tested elsewhere and the relative differences between the interventions as compared using a common currency. In addition, the review has highlighted the gaps in economic evaluation methods, and steers researchers and evaluators towards improving their practice and reporting high-quality economic findings, while building on existing knowledge.
CONCLUSIONS
Wide-scale implementation of health behaviour interventions to curb the growing chronic disease burden in developed nations is an important population health objective. This review provides the current state of evidence for economic evaluations in 64 studies across the four key behaviours of smoking, alcohol consumption, diet, and physical activity. There was wide variation in terms of sample populations, interventions, settings, and intervention outcomes, in addition to the use of varying economic methods. Similarly, the quality of the studies in the review was wide-ranging, with many studies having major limitations when evaluated against a comprehensive economic evaluation checklist. Nevertheless, overall, most health behaviour interventions were very good value on economic grounds, especially smoking-cessation counselling with pharmacotherapies and interventions targeting high-risk populations. Further economic evaluations of stronger quality are necessary to establish the cost-effectiveness of interventions for diet, alcohol consumption, and physical activity. Care is needed when generalizing these findings in local settings, and economic re-analysis is recommended to account for different disease prevalences, healthcare systems (prices and access to healthcare), and purchasing powers. Further evaluations should target multiple behaviour interventions, due to the potential synergy to be gained. Markov modelling and Monte Carlo simulation approaches (and their quality assessment) will be inevitable in future investigations of behaviour change interventions, because of the complexity of treatment effects, multiple behaviour interactions, and the lifelong time frame advocated for both lifestyle improvements and cost-effectiveness analysis.
